AbbVie secures another Humira settlement
AbbVie and Amgen settle Humira clash
AbbVie has taken Sandoz to court over its biosimilar version of Humira (adalimumab), heightening the dispute between the pair.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AbbVie, Humira, Sandoz, patent infringement, generics, BPCIA, injunction, biosimilars